Ads
related to: novartis- About Us
We Help You Find the Right Software
With a Free, Expert Consultation
- Compare Software Reviews
Learn About Software Systems
And Read User Reviews
- Research & Advice
The Latest Software Research
For Buyers Like You
- Buyer's Guide
Explore Common Features And
Benefits of Medical Software
- About Us
Search results
Novartis (NVS) Presents Positive Data on Renal Drugs at ERA
Zacks· 1 day agoNovartis (NVS) presents data on Fabhalta in adult patients with C3 glomerulopathy and atrasentan in...
Novartis’ atrasentan shows to reduce proteinuria in Phase III IgAN trial
Clinical Trials Arena via Yahoo Finance· 22 hours agoNovartis has unveiled interim results from the Phase III ALIGN clinical trial where atrasentan...
US pharma giant Cencora says Americans' health information stolen in data breach
TechCrunch· 4 days agoU.S. pharmaceutical giant Cencora says it is notifying affected individuals that their personal and...
Dr. Reddy’s and Novartis sign distribution agreement for anti-diabetes products
Pharmaceutical Technology via Yahoo Finance· 22 hours agoDr. Reddy's Laboratories' Russian subsidiary has signed an agreement with Novartis Pharma to carry...
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further...
KOIN News 6 Portland· 3 days ago...atrasentan is a potent, selective ETA receptor antagonist with potential to reduce persistent...
UBS Group AG Has $167.76 Million Stock Holdings in Novartis AG (NYSE:NVS)
ETF DAILY NEWS· 7 days agoUBS Group AG trimmed its stake in shares of Novartis AG (NYSE:NVS – Free Report) by 9.9% during the fourth quarter, according to its most recent disclosure with the Securities ...
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing...
KOIN News 6 Portland· 3 days agoNovartis today presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G...
Novartis to seek approvals in two rare kidney diseases after positive Phase 3 trials
Endpoints News· 3 days agoNovartis is building out its rare kidney disease portfolio with two batches of Phase 3 data at the...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 20 hours agoAcne Vulgaris Market to Register Sustainable Growth by 2034, Examines DelveInsight | Key Companies - Dermata Therapeutics, AstraZeneca, Novartis Pharmaceuticals, UCB Pharma ...
Novartis Patient Information Leaked in Third-Party Data Breach at Lash Group | JD Supra
JD Supra· 4 days agoIn this notice, Lash Group explains that the incident resulted in an unauthorized party being able to access sensitive information belonging to patients enrolled in “patient support programs ...
